Dr Walter Straus | Associate Vice President, Therapeutic Area Head, Clinical Safety and Risk Management
Merck Research Laboratories

Dr Walter Straus, Associate Vice President, Therapeutic Area Head, Clinical Safety and Risk Management, Merck Research Laboratories

Walter L. Straus is the Associate Vice President, Therapeutic Area Head, Clinical Safety and Risk Management at Merck Research Laboratories, Merck & Co, Inc., where he leads a team that conducts research in vaccine-preventable and other infectious diseases, as well as oncology. The work spans early discovery through post-licensure assessments. As a result, he has involvement in issues ranging from molecular epidemiology, to development of patient-reported outcome measures for use in clinical trials, through to assessment of the safety and effectiveness of marketed products. While much of his work is done in support of clinical research, his group is also involved in basic research. Additionally, since so much of the burden of vaccine preventable diseases falls on developing countries, Dr. Straus’ team is also involved in epidemiologic assessment of disease in areas of the world normally outside of sphere that has historically characterized pharmaceutical development. This activity has led to his active involvement in internal discussions about proper research ethical considerations for research in developing countries. Dr. Straus is a former Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention, and has served as a consultant to the World Health Organization and other non-governmental organizations. His primary medical ethics focus is upon ensuring appropriate research protection for vaccine research in developing countries. His team is active in scientific presentations and publications. He serves as a Technical Consultant to the AHRQ Center for Education and Research on Therapeutics at the University of Alabama, and holds an adjunct appointment with the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania.


DC Co-conference Day 2 April 4 @ 11:55

Panel: Improving active vaccine safety surveillance in resource-limited settings

  • Understanding PV requirements in Latin America, how is the environment changing?
  • The use of self-control approaches for investigation of vaccine adverse events
    • Examples
  • Outlook for the future of international PV

DC Co-conference Day 2 April 4 @ 3:40

Vaccine pharmacovigilance: the once and future challenges

  • Data sources for vaccine safety are advancing; the introduction of more sophisticated data sources and methods may help address some of the shortcomings of the most established pharmacovigilance tools.
  • The introduction of novel vaccines into an increasingly globalized health market creates an increasing demand for robust and timely vaccine safety monitoring systems.
  • The introduction and impact of successful vaccines and public health implementation programs have been paralleled by advances in communication technologies which have coalesced to raise societal expectations for vaccine safety.

back to speakers